FDA Approves Teclistamab in Combination with Daratumumab Hyaluronidase-fihj for Relapsed or Refractory Multiple Myeloma By Ogkologos - March 25, 2026 87 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the MajesTEC-3 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Highlights the Importance of a Strong EU Commitment Towards Robust Science and Innovation Policies Following Meeting of EU Research Ministers on 29 May... Metastatic Breast Cancer: ESMO Clinical Practice Guideline EMA Recommends Extending Indications for Decitabine / Cedazuridine MOST POPULAR Clinical Trial Results Support Uninterrupted Use of Imatinib for Some Gastrointestinal... September 19, 2024 Adjusting to the Challenges of Life After Cancer: An Expert Perspective May 5, 2022 Diverse Genomic and Histologic Mechanisms of Resistance to KRASG12C Inhibition Described June 25, 2021 Bowel scope screening to stop in England January 14, 2021 Load more HOT NEWS Could A Form of Cell Death Enhance Cancer Immunotherapy? Targeting CLDN18.2 with Zolbetuximab Prolongs Survival When Combined with mFOLFOX6 in... Women and girls in science: We won’t stop pushing for progress SBRT Emerging as an Important Treatment for Early-Stage Kidney Cancer
